IL279315A - 19-NOR C3,3-dimuter C21-N-pyrazolyl steroid and methods of using it - Google Patents
19-NOR C3,3-dimuter C21-N-pyrazolyl steroid and methods of using itInfo
- Publication number
- IL279315A IL279315A IL279315A IL27931520A IL279315A IL 279315 A IL279315 A IL 279315A IL 279315 A IL279315 A IL 279315A IL 27931520 A IL27931520 A IL 27931520A IL 279315 A IL279315 A IL 279315A
- Authority
- IL
- Israel
- Prior art keywords
- disubstituted
- methods
- pyrazolyl steroid
- steroid
- pyrazolyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| PCT/US2019/036848 WO2019241442A1 (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL279315A true IL279315A (en) | 2021-01-31 |
Family
ID=67211854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279315A IL279315A (en) | 2018-06-12 | 2020-12-09 | 19-NOR C3,3-dimuter C21-N-pyrazolyl steroid and methods of using it |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20210338692A1 (https=) |
| EP (1) | EP3806863A1 (https=) |
| JP (3) | JP2021527092A (https=) |
| KR (1) | KR20210021005A (https=) |
| CN (2) | CN112533611A (https=) |
| AU (2) | AU2019287491B2 (https=) |
| CA (1) | CA3103421A1 (https=) |
| IL (1) | IL279315A (https=) |
| MA (1) | MA52894A (https=) |
| MX (2) | MX2020013557A (https=) |
| SG (1) | SG11202012344RA (https=) |
| WO (1) | WO2019241442A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| KR20220112803A (ko) * | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| KR20230041049A (ko) * | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| KR20230136599A (ko) * | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
| US20240245711A1 (en) * | 2021-03-17 | 2024-07-25 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| WO2022232504A1 (en) * | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| EP4329769A1 (en) * | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| IL315023A (en) * | 2022-02-16 | 2024-10-01 | Sage Therapeutics Inc | Neuroactive steroids for treatment of cns-related disorders |
| WO2025175214A1 (en) * | 2024-02-16 | 2025-08-21 | Engrail Therapeutics, Inc. | Methods of treating generalized anxiety disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| KR20240157128A (ko) * | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3504189A1 (en) * | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
-
2019
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko active Pending
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en not_active Ceased
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491B2/en active Active
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
- 2020-12-11 MX MX2025000166A patent/MX2025000166A/es unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en not_active Abandoned
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
-
2024
- 2024-12-12 US US18/978,431 patent/US20250339447A1/en active Pending
-
2025
- 2025-04-10 JP JP2025064902A patent/JP2025108553A/ja active Pending
- 2025-08-15 AU AU2025217363A patent/AU2025217363A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112533611A (zh) | 2021-03-19 |
| JP2024028849A (ja) | 2024-03-05 |
| CN117959309A (zh) | 2024-05-03 |
| JP2025108553A (ja) | 2025-07-23 |
| MX2025000166A (es) | 2025-03-07 |
| AU2019287491B2 (en) | 2025-05-15 |
| US20210338692A1 (en) | 2021-11-04 |
| KR20210021005A (ko) | 2021-02-24 |
| US20250339447A1 (en) | 2025-11-06 |
| WO2019241442A1 (en) | 2019-12-19 |
| MA52894A (fr) | 2021-04-21 |
| JP2021527092A (ja) | 2021-10-11 |
| TW202005653A (zh) | 2020-02-01 |
| EP3806863A1 (en) | 2021-04-21 |
| SG11202012344RA (en) | 2021-01-28 |
| CA3103421A1 (en) | 2019-12-19 |
| US20200113917A1 (en) | 2020-04-16 |
| AU2025217363A1 (en) | 2025-09-04 |
| MX2020013557A (es) | 2021-05-27 |
| AU2019287491A1 (en) | 2021-01-07 |
| US20220323462A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279315A (en) | 19-NOR C3,3-dimuter C21-N-pyrazolyl steroid and methods of using it | |
| IL273126A (en) | 19-NOR C3,3-dimethyl C21-N-pyrazolyl steroid and methods of using it | |
| IL278487B (en) | 19- nor c3, 3- dimethomer c21- n- pyrazole Steroids and methods of using them | |
| AU2019392680B2 (en) | Neuroactive steroids and their methods of use | |
| IL275757A (en) | Steroids and always their antibody | |
| IL315950B1 (en) | 19-NOR C3,3-dimethomer C21-N-pyrazolyl steroid crystalline | |
| IL273099A (en) | Neuroactive steroids and methods of using them | |
| CA3287794A1 (en) | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof | |
| GB201805302D0 (en) | Ensemble Model Creation And Selection | |
| EP3848861A4 (en) | PLANNING DEVICE, PLANNING PROCEDURE AND PLANNING PROGRAM | |
| SG11202107530WA (en) | Steroid compound, and use thereof and preparation method therefor | |
| EP3739571A4 (en) | VOICE SYNTHESIS PROCESS, VOICE SYNTHESIS DEVICE AND PROGRAM | |
| EP3911331A4 (en) | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF | |
| PL3858833T3 (pl) | Pochodna aminonorbornanu oraz sposób jej wytwarzania i zastosowanie | |
| ZA202100093B (en) | Neuroactive steroids and methods of preparation | |
| GB2589260B (en) | Pipe structure and construction method | |
| SG10201908033QA (en) | Tape, tape attaching method, and tape expanding method | |
| TWI923545B (zh) | 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 | |
| HK40051026A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| HK40074862A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| GB202004486D0 (en) | Flushing devices and methods | |
| HK40063679A (en) | Neuroactive steroids and their methods of use | |
| HK40042062A (en) | Steroids and antibody-conjugates thereof | |
| HK40047578A (en) | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof | |
| HK40033089A (en) | Neuroactive steroids and their methods of use |